Parameter
| Biomarker | PIK3CA | Full name | Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | Molecular Type | Nucleic acid |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Prognosis |
| Disease | Breast Cancer | Disease Subtypes | / | ||
| Organ | Breast | Test Sample / Technology Platform | Tumor tissue / ctDNA (NGS, dPCR) | ||
| Pathobiological Mechanisms | The PIK3CA mutation activates the PI3K-AKT-mTOR signaling pathway, promoting cell proliferation and inhibiting apoptosis, and is associated with resistance to endocrine therapy. | ||||
| Clinical Availability Status | Clinical application (targeted therapy guidance): For advanced patients with PIK3CA mutations, PI3K inhibitors (such as aprepitant) can be used in combination with endocrine therapy. | ||||
| Notes and Dynamics | The combination therapy of PI3K inhibitors and immune checkpoint inhibitors is currently in the clinical trial stage for patients with PIK3CA mutations. | ||||